Bisoprolol

Bisoprolol is a synthetic beta-adrenergic receptor antagonist, commonly called a beta blocker, and is described as cardioselective because at usual doses it acts mainly on the beta-1 receptors that predominate in the heart rather than the beta-2 receptors of the airways and blood vessels ^[1]. By occupying beta-1 receptors it blunts the stimulating effect of adrenaline and related catecholamines on the heart, slowing the heart rate and reducing the force of its contractions. It is a long-acting agent, which allows once-daily dosing, and is usually supplied as bisoprolol fumarate in tablet form.

The drug is used across several cardiovascular conditions. It lowers blood pressure in hypertension, relieves the chest pain of angina by reducing the heart's workload and oxygen demand, and helps control the rate of certain fast or irregular heart rhythms ^[1]. One of its most significant roles is in chronic heart failure with reduced pumping function, where it is added to standard therapy and gradually increased to a target level over weeks ^[1]. It is also used to help protect the heart in people who have had a heart attack or who are at cardiovascular risk.

Bisoprolol is one of a small number of beta blockers with strong trial evidence in heart failure. The landmark CIBIS-II study, a large randomized, placebo-controlled trial, was stopped early when bisoprolol was found to significantly reduce all-cause mortality and sudden death in patients with stable, moderate-to-severe heart failure already receiving standard treatment ^[1]. A combined analysis of the earlier CIBIS and CIBIS-II trials confirmed a substantial reduction in death and hospitalization with a favorable balance of benefit and risk ^[2]. Broader meta-analysis found that the survival benefit of bisoprolol is similar to that of other proven heart-failure beta blockers such as carvedilol and metoprolol and applies across the range of disease severity ^[3]. Later work in older patients showed that the resting heart rate reached after gradual dose increase, rather than the dose itself, best predicted outcomes ^[4].

Bisoprolol was patented in the 1970s and introduced for medical use in the 1980s, reaching the United States market in the early 1990s. It is included on the World Health Organization's Model List of Essential Medicines and is widely available as an inexpensive generic, remaining among the more commonly prescribed cardiovascular drugs. It is sometimes combined in a single tablet with a diuretic such as hydrochlorothiazide for the treatment of high blood pressure.

In practice, treatment is usually started at a low level and increased slowly, since abrupt introduction of a strong dose or sudden withdrawal can be poorly tolerated in heart patients ^[1]. Its relative selectivity for beta-1 receptors makes it somewhat better suited than nonselective beta blockers to people with airway disease, although caution is still advised and the selectivity diminishes at higher doses. As with the class as a whole, it is generally stopped gradually rather than all at once to avoid a rebound worsening of heart symptoms.

Bisoprolol is a prescription medicine. Common side effects include tiredness, a slow heart rate, cold hands and feet, dizziness, low blood pressure, vivid dreams, and sometimes sexual difficulties. In heart failure the dose must be raised slowly, because starting too high or too fast can briefly worsen symptoms. It should never be stopped abruptly, since that can trigger a rebound in heart rate and chest pain. It is avoided in very slow heart rates, high-degree heart block, decompensated heart failure, and cardiogenic shock, and used cautiously in asthma; combining it with verapamil or diltiazem can slow the heart dangerously, and it can mask the warning signs of low blood sugar.

Bisoprolol reduces the natriuretic effect of thiazide diuretics like hydrochlorothiazide, though the precise mechanism remains uncertain ^[13]. This is a pharmacodynamic interaction; bisoprolol does not alter thiazide levels (pharmacokinetic), but instead opposes the kidney's salt-wasting response to the diuretic through beta-adrenergic blockade. Unlike ACE inhibitors and angiotensin receptor blockers, which enhance thiazide natriuresis by interfering with tubuloglomerular feedback in the afferent arteriole, beta-blockers reduce natriuresis while preserving the normal tubuloglomerular feedback mechanism ^[13]. What remains unstudied: bisoprolol interactions with loop diuretics, potassium-sparing diuretics, or modern diuretic combinations; the magnitude of this effect in hypertensive patients on long-term therapy; and whether calcium channel blockers show the same blunting as beta-blockers.

Checking a whole stack? Run it through interactions + stacks.

Bisoprolol is a second-generation, highly beta-1 selective adrenergic blocker introduced by the German company E. Merck in the 1980s for hypertension and angina. Its most important chapter came through the Cardiac Insufficiency Bisoprolol Study program, whose second trial, CIBIS-II, was a large European placebo-controlled study of patients with chronic heart failure. CIBIS-II was stopped early after a planned interim analysis because bisoprolol produced a clear reduction in all-cause mortality and sudden death, helping to establish beta-blockade as standard heart-failure therapy. A later trial, CIBIS-III, showed that initiating treatment with bisoprolol before an ACE inhibitor is a viable strategy. Bisoprolol is now a generic medicine on the World Health Organization's List of Essential Medicines.

Bisoprolol enjoys a strong reputation as one of the most cardioselective beta-blockers, a property that improves tolerability and permits cautious use in many patients who also have airway disease. It is one of only a few beta-blockers with robust randomized evidence for improving survival in heart failure with reduced ejection fraction, which places it among the guideline-preferred agents. Its once-daily dosing and predictable behavior make it a dependable choice for hypertension, angina, and rate control as well. Clinicians regard it as a well-validated, everyday cornerstone of cardiovascular care.